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Abstract
Aberrant DNA methylation is critical for development and progression of breast cancer. We investigated the association of
CpG island methylation in candidate genes and clinicopathological features in 65 African-American (AA) and European-
American (EA) breast cancer patients. Quantitative methylation analysis was carried out on bisulfite modified genomic DNA
and sequencing (pyrosequencing) for promoter CpG islands of p16, ESR1, RASSF1A, RARb2, CDH13, HIN1, SFRP1 genes and
the LINE1 repetitive element using matched paired non-cancerous and breast tumor specimen (32 AA and 33 EA women).
Five of the genes, all known tumor suppressor genes (RASSF1A, RARb2, CDH13, HIN1 and SFRP1), were found to be
frequently hypermethylated in breast tumor tissues but not in the adjacent non-cancerous tissues. Significant differences in
the CDH13 methylation status were observed by comparing DNA methylation between AA and EA patients, with more
obvious CDH13 methylation differences between the two patient groups in the ER- disease and among young patients
(age,50). In addition, we observed associations between CDH13, SFRP1, and RASSF1A methylation and breast cancer
subtypes and between SFRP1 methylation and patient’s age. Furthermore, tumors that received neoadjuvant therapy
tended to have reduced RASSF1A methylation when compared with chemotherapy naı ¨ve tumors. Finally, Kaplan Meier
survival analysis showed a significant association between methylation at 3 loci (RASSF1A, RARb2 and CDH13) and reduced
overall disease survival. In conclusion, the DNA methylation status of breast tumors was found to be significantly associated
with clinicopathological features and race/ethnicity of the patients.
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Introduction
Breast cancer is the most commonly diagnosed cancer among
women in the United States, with .130,000 cases diagnosed
yearly [1]. Among the different population groups within the
United States, the overall breast cancer incidence is highest in
European American (EA) women followed by African American
(AA) women [2]. When breast cancer risk is stratified by age, EA
women have the highest age-adjusted breast cancer incidence
among women .50 years whereas in the ,50 age group, the
pattern is different with the EA women having lower incidence
rates than AA [3]. In stark contrast to the incidence rates, AA
women have generally higher age-adjusted mortality rates than EA
women, accounting for the highest breast cancer mortality rates
among all US population groups [3]. It has been suggested that the
higher morality and lower survival rates among AA women are all
due to factors associated with lower socioeconomic status and
delayed disease diagnosis [4–7]. While socioeconomic factors are
undoubtedly very important, they may not explain the full
magnitude of the US survival health disparity in breast cancer
[8]. Therefore, solving the racial disparity will require under-
standing possible tumor biological differences between population
groups beyond the current knowledge of differences in hormone
receptor status and disease grade. Breast cancer is a heterogeneous
disease consisting of five major breast tumor subtypes: basal,
human epidermal growth factor receptor 2 (HER2)-positive/
estrogen receptor (ER)-negative, luminal A, luminal B, and normal
like [9,10]. Young AA women are at an increased risk to develop
basal-like breast tumors, which tend to be both more aggressive
and therapy resistant than the luminal type tumors and also have
an increased propensity to metastasize to brain and lung [10–12].
AA women also experience almost twice the prevalence of the
triple-negative disease (ER, progesterone receptor [PR], and
human epidermal growth receptor 2 [HER2] negative) when
compared with EA women [11,13]. It has been hypothesized that
the higher likelihood of developing triple-negative breast cancer
might contribute to the higher mortality from breast cancer
experienced by AA women compared with EA women [1,13,14].
Recent large scale gene expression profiling studies has confirmed
the identities of these 5 subtypes based on their distinct gene
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alterations that impact the expression patterns of individual genes
or entire signatures in breast cancer have been described and
include; inherited BRCA1 and BRCA2 [16], p53 [17], and H-ras-
1 mutations [18] and overexpression of cyclin D1 [19]. Some of
these genetic alterations tend to occur more commonly in tumors
of AA than EA patients as shown for p53 and BRCA1/2
mutations [20,21]. Moreover, Loo and coworkers observed
significant differences in genomic copy number alterations in
triple negative tumors from AA and EA women [22], whereas
other investigators have reported differences in the gene expres-
sion profiles between AA and EA tumors in pathways related to
tumor angiogenesis and chemotaxis [23].
In addition to somatic mutations, tumor DNA methylation
pattern were found to show differences between breast cancer
subtypes [24–27]. Another report also observed that hormone
receptor-negative tumors from young AA patients show distinct
DNA hypermethylation at certain loci when compared with EA
tumors, suggesting candidate tumor biological differences between
the two patient groups as they relate to cancer epigenetics [28].
The purpose of the present study was to test the hypothesis that
tumor DNA methylation is different between AA and EA patients,
as reported previously in one publication, and to characterize the
relationship between the DNA methylation status of several breast
cancer-related genes and patient characteristics or tumor markers.
Materials and Methods
Tissue
Fresh-frozen tissue samples corresponding to paired normal and
breast tumor specimen from 65 patients (32 AA, and 33 EA
women) were obtained from University of Maryland Medical
Center (UMD) and Veterans Administration (VA) Hospital,
Baltimore MD., and processed as previously described [29].
Clinical and pathological information (e.g., tumor receptor status)
was obtained from medical records and pathology reports. Disease
staging was performed according to the TNM system of the
American Joint Committee on Cancer/Union Internationale
Contre le Cancer (AJCC/UICC). The Nottingham system was
used to determine the tumor grade. The collection of tumor
specimens and clinical and pathological information was reviewed
and approved by the University of Maryland Institutional Review
Board for the participating institutions (UMD protocol 0298229).
IRB approval of this protocol was obtained at all institutions
(UMD, VA and Howard University). The tissues were taken as
distant as possible during routine surgery and none of the adjacent
normal tissues contained visible tumor contamination by histolog-
ical analysis. High molecular weight genomic DNA was isolated
from fresh-frozen breast tissues using the DNeasyH isolation kit
following the manufactures directions for purification from human
tissues (Qiagen, Valencia, CA). DNA concentration was measured
using the Nanodrop Spectrophotometer (Nanodrop, Wilmington,
DE).
Bisulfite modification, PCR, and pyrosequencing analysis
High molecular weight genomic DNA extracted from breast
tissues was modified using sodium bisulfite treatment [30]. Briefly,
genomic DNA (2 ı `g) was denatured in 0.3 mol/L NaOH at 37uC
for 15 minutes; sodium bisulfite and hydroquinone were added to
final concentrations of 3.1 mol/L and 0.5 mmol/L, respectively.
The reaction was incubated at 50uC for 16 hours and desalted
using Wizard DNA purification resin (Promega) according to the
instruction of the manufacturer. Bisulfite modification was
completed by DNA desulfonation in 0.3 mol/L NaOH at 37uC
for 15 minutes. Modified DNA was precipitated with ethanol,
washed in 70% ethanol, dried, and dissolved in 50 ı `L of TE buffer.
The PCR primers were designed to assay the methylation status of
CpGs within 0.5 kb from the transcription start site. The CpG
islands interrogated were previously described; p16, RASSF1A,
RARb2 and ESR1 [31,32], LINE1, CDH13, HIN1 [33] and SFRP1
Figure 1. Quantitative DNA methylation analysis in human breast tissues. The percentage of DNA methylation levels at promoter CpG
islands were analyzed in bisulfite-modified genomic DNA extracted from matched pairs of non-cancerous (normal) and breast tumors (tumor) tissue
samples obtained from AA and AE cancer patients. Y axis, percentage of methylated cytosines in the samples as obtained from pyrosequencing. X
axis, normal and tumor tissues obtained from AA and EA. P value is indicated for each gene (Mann-Whitney). Adj. P: adjusted P value (Bonferroni).
doi:10.1371/journal.pone.0037928.g001
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listed in the Table S1. Either one-step or two-step PCR reactions
were carried out using 2 ı `L of bisulfite-converted genomic DNA
and either one or two sets of different bisulfite PCR primers in a
standard PCR reaction mix. One of the primers (reverse primer) in
the final PCR reaction was biotinylated to create an ssDNA
template for the pyrosequencing reaction. Where indicated, we
used a previously described amplification protocol [35] based on
the universal primer approach. Briefly, the biotinylated reverse
primer was substituted with a 59 tailed unlabeled reverse primer
and a biotinylated universal primer at a ratio of 1:9 in the PCR
reaction. The integrity of the PCR product was verified on 1.5%
Table 1. Demographic, clinicopathologic characteristics and percent ancestry of breast cancer patient cases.
All
N=67
AA
1
N=32
EA
2
N=35 P-value
3
Mean ± SD t test
Age (years) 54±15.8 52.9±16.1 54.9±15.7 0.62
Tumor size (cm across) (n=60) 4.2±2.7 3.8±2.3 4.5±3.0 0.25
West-African ancestry (%) among AA (range: 67% to 95%; n=32) 83.2±8.7 (16.0±8.8) ,0.001
European ancestry (%) among EA (range: 75% to 100%; n=35) (2.2±0.5) 97.6±4.7 ,0.001
NN N
Fisher’s exact
test
ER Status Negative 34 16 18
Triple-negative and/or basal-like
4 16 8 8
HER2-positive 11 8 3
Positive 33 16 17 1.0
5
Luminal A 21 12 9
Luminal B (ER/HER2-positive) 10 3 7
TNM Stage I 62 4
II 46 24 22
III 15 6 9 0.63
Grade 1 81 7
2 20 8 12
3 29 18 11 0.029
6
Unknown 10 5 5
p53 mutation Negative 51 25 26
Positive 16 7 9 0.78
Menopause No 26 14 12
Yes 33 14 19 0.44
6
Unknown 84 4
Income Less than $15,000 12 10 2
$15,000 to $60,000 26 13 13
More than $60,000 11 1 10 ,0.01
6
Unknown 18 8 10
Body mass index #24.9 18 7 11
25.0 to 29.9 15 5 10
$30.0 29 17 12 0.25
6
Unknown 53 2
Neoadjuvant
therapy
No 53 30 23
Yes 9 1 8 0.026
6
Unknown 51 4
SD=standard deviation.
1AA=African-American,
2EA=European-American. Race/ethnicity is determined by self-identification;
3AA versus EA;
4basal-like=ER-negative, HER2-negative, and either cytokeratin 5/6-positive or EGFR-positive;
5ER-negative versus ER-positive;
6Unknown not included.
doi:10.1371/journal.pone.0037928.t001
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was immobilized on streptavidin-Sepharose beads (Amersham),
washed, and denatured, and the biotinylated strands were released
into annealing buffer containing the sequencing primer. Pyrose-
quencing was done using the PSQ HS96 Gold SNP Reagents on a
PSQ 96HS machine (Qiagen). Bisulfite-converted DNA from
blood of normal volunteers and blank reactions, with water
substituted for DNA, served as negative control and bisulfite-
converted SssI methylase–treated blood DNA served as a positive
control. Each bisulfite PCR and pyrosequencing reaction was
done at least twice. A typical example of methylation raw data
presented as pyrogram for CDH13 CpG island is shown in
Pyrogram Data S1.
Statistical analysis
Statistical analyses were performed using R, a language and
environment for statistical computing by R Development Core
Team at R Foundation for Statistical Computing, and packages in
Bioconductor [36]. Specifically, survival analysis was performed
using survival package. Z scores for DNA methylation levels of
each gene was calculated across all tumor samples. Groups of
samples were compared by Mann-Whitney test with Bonferroni
correction.
Results
Methylation status of gene promoter CpG islands in
matched normal and breast cancer tissues
We evaluated the DNA methylation status for a panel of genes
in paired adjacent non-cancerous and breast tumor specimens
from a total of 65 patients (32 AA and 33 EA women). The
demographic, clinicopathological characteristics and percent
ancestry of the patient samples are presented in Table 1. The
clinicopathological features did not differ significantly between the
two patient groups by age at diagnosis, ER status, tumor size and
disease stage, lymph node status or tumor p53 status. There are
equal numbers of AA and EA patients with triple-negative or
basal-like tumors in the data set. AA patients tended to have
higher grade tumors more frequently than EA patients. We
investigated the methylation status of 8 genes of which 6 are
known growth suppressor genes namely p16, RASSF1A, RARb2,
CDH13, HIN1 and SFRP1 genes, with the other 2 encoding the
Figure 2. Promoter methylation and gene expression. The ratio of gene expression data of tumor to non-cancerous (normal) from a genome-
wide gene expression microarray [23] was correlated with the methylation difference between the tissue pairs. The log 2 ratio of gene expression in
matched pair tumor and normal is shown on Y axis. The relative methylation frequency is shown on the X-axis. P value and the correlation index; r
(Rho) values are from Spearman rank correlation analysis.
doi:10.1371/journal.pone.0037928.g002
DNA Methylation Changes and Breast Cancer
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37928estrogen receptor alpha (ESR1) or representing a global methyl-
ation marker, the LINE1 repetitive elements [31–34]. We used
pyrosequencing assays to analyze the methylation status of these
genes in the 65 matched tissue pairs. For each gene studied, the
percentage (%) of methylation at a specific promoter was
compared between the non-cancerous and the cancerous tissues
(Fig. 1). The pyrosequencing analysis was repeated only with cases
that were not exposed to neoadjuvant therapy (Fig S1). There was
little difference from all cases analyzed. Five of the 8 genes
(RASSF1A, RARb2, CDH13, HIN1 and SFRP1) were frequently
hypermethylated in the tumor samples. ESR1 was uncommonly
methylated and the p16 gene was not methylated in either tumor
or non-cancerous breast tissues. The LINE1 repetitive element, a
global methylation marker, showed a distinct methylation pattern
and was found to be hypermethylated in both the malignant and
non-cancerous breast tissue samples, as one may expect with a
significant reduction of % LINE1 methylation in tumors compared
to non-cancerous tissue samples. To further examine the
relationship between the methylation profile with patient charac-
teristics and tumor markers, we focused on the 4 genes (RASSF1A,
RARb2, CDH13 and SFRP1) that showed the highest relative
changes in tissue methylation status across the 65 tissue pairs.
Correlation between promoter methylation and gene
expression level
To assess the biological significance of promoter methylation in
the breast tumor samples, we correlated the relative methylation
frequency with gene expression data from a previously described
genome-wide gene expression study [23]. As shown in figure 2, the
Spearman rank correlation revealed significant inverse association
between promoter methylation and gene expression for RARb2
(r=20.322; p,0.05) and SFRP1 (r=20.513; p,0.001), suggest-
ing that silencing of these genes is at least partly caused by
promoter methylation. We did not observe a significant association
between methylation and gene expression for the RASSF1A and
CDH13 loci, suggesting that other repression mechanisms like
chromatin silencing or methylation at other CpG island are
important in RASSF1A and CDH13 silencing.
Relationship between gene methylation status and
patient characteristics
To further explore the association of the tumor methylation
status with patient characteristics such as age, race/ethnicity and
ER status, we initially examined gene methylation differences
between AA and EA women (Fig. 3a). The statistical analysis
revealed difference in the methylation status between AA and EA
patients for the CDH13 gene (p=0.023), but not for any other
gene. We repeated the analysis for AA and EA women that were
not exposed to neoadjuvant therapy, there was little difference
from all cases analyzed (Fig S2a). When we studied the relative
methylation frequency after stratification into two age groups with
the cutoff point at age 50, we found that young (,50 years of age)
and ER-negative AA patients had a significantly higher methyl-
Figure 3. Gene methylation status and patient characteristics.
A. Relative methylation frequency (% methylation in tumor minus %
methylation in adjacent normal) stratified by race; AA (n=32) and EA
(n=33; Mann-Whitney). Adj. P: adjusted P value (Bonferroni) B. Relative
methylation frequency stratified by ER- negative (2) patients with
age,50 (17 cases in total; 8 AA cases and 9 EA cases) P value is shown
(Mann-Whitney). C. Percentage methylation frequency in breast tumor
cases stratified by age (age,50: n=31; age$50: n=34). P value is
shown (Mann-Whitney).
doi:10.1371/journal.pone.0037928.g003
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(p,0.005; Fig. 3b), while the analysis of RASSF1A, RARb2 and
SFRP1 did not find significant differences in this subgroup analysis.
In contrast, we could not detect any methylation differences
between AA and EA patients in the ER-positive disease, indicating
that the CDH13 differences between the two patient groups are
restricted to ER-negative tumors. These findings are consistent
with findings by others that methylation differences in breast
tumors between AA and EA patients are perhaps restricted to ER-
negative tumors [28]. To ascertain whether individual ancestry is
influencing the methylation status, we carried out a correlation
analysis between West African score (for AA) or European score
(for EA) and methylation score (Fig S2b). There was no significant
correlation between CDH13 methylation and individual ancestry
score suggesting that no functional African ancestry related Single
nucleotide polymorphic marker(s) is affecting CDH13 methyla-
tion. Lastly, age itself was modestly associated with the methyl-
ation status at the SFRP1 locus in the tumor samples tumor
samples (p=0.084; Fig. 3c). This change is not correlated with
normal samples was there was little variation in % methylation in
normal tissues (as shown in Fig. 1). Overall, we observed the trend
that tumors of older patients tend to have increased promoter
methylation.
Relationship between gene methylation and tumor
subtypes
Next, we analyzed tumor characteristics to investigate whether
there is a correlation of % methylation with clinical outcomes
(Fig. 4a–c). We observed that triple-negative breast cancers tended
to have increased CDH13 methylation (p=0.044) and a decreased
methylation of the RASSF1A (p,0.02) and SFRP1 (p,0.05,
Fig. 4a) genes when compared with other subtypes. The closely
related basal-like tumors also had decreased RASSF1A methylation
(p=0.052; Fig. 4b) when compared with other breast cancer
subtypes, while the luminal A tumors tended to have a reduced
CDH13 methylation (p,0.03; Fig. 4c).
Correlating gene methylation changes with neoadjuvant
therapy
We investigated the association of relative methylation changes
in breast tumors with neoadjuvant therapy by comparing tumors
that received neoadjuvant therapy (n=9) to those that did not
(n=53; Mann-Whitney). Tumors that received neoadjuvant
therapy tended to have reduced RASSF1A methylation when
compared with tumors that did not (p,0.005; Fig. 5), suggesting
that neoadjuvant therapy may affect RASSF1A methylation.
Methylation signatures that are associated with survival
and ethnic difference
We investigated the association between DNA methylation
status and outcome of the patients. While the DNA methylation
status of individual genes were not associated with patients survival
(data not shown), we tested if the combination of genes could
improve the ability in detecting the association between methyl-
ation status and disease outcome. We integrated the DNA
methylation status of multiple genes by summing their methylation
Figure 4. Gene methylation status and tumor subtypes.
Percentage methylation frequency stratified by subtype: A. Triple-
negative (TN) tumors (n=14) versus others (n=43), B. Basal-like (BL)
tumors (n=13) versus others (n=45). C. Luminal A (LumA) tumors
(n=21) versus others (n=37; Mann-Whitney).
doi:10.1371/journal.pone.0037928.g004
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methylated more in AA patients (RASSF1A, RARb2 and CDH13;
shown in Fig. 3B) were combined, the sum of methylation scores
become significantly higher in AA tumors (p=0.035; Fig. 6A).
Furthermore, patients with high methylation scores revealed poor
outcome (Fig. 6B), implying the potential association between
methylation of these genes and poor outcome of AA patients.
Discussion
Many existing data indicates that aberrant DNA methylation is
associated with breast cancer risk; however, to our knowledge
there is only one published report to suggest an association
between DNA methylation changes and invasive ductal breast
cancers comparing AA patients with EA patients [28]. In the
present study, we used quantitative DNA methylation analysis to
measure the methylation frequency in 6 known tumor suppressor
genes, the estrogen receptor alpha and 1 global methylation
marker to delineate their methylation differences in AA and EA
patients and to characterize the relationship between the DNA
methylation status and patient characteristics or tumor markers.
Our most notable observation is the presence of a significantly
higher methylation at a CpG site in the CDH13 gene in breast
tumor samples from AA women when compared with EA women
among young and ER-negative patients. The CDH13 gene is a
well-known tumor suppressor gene whose protein product is a
putative mediator of cell-cell interaction and cancer cell invasion
and metastasis [37]. Thus CDH13 hypermethylation may
contribute to the distinct molecular alterations hypothesized for
AA and EA tumors that may play a role in the early onset of breast
cancer that lacks ER expression. In humans, methylation changes
are more and more recognized as part of pathologic aging
physiology [31,38]. While associations between gene promoter
methylation and age have been reported, there is inconsistency in
findings from different groups. We observed that age was
significantly associated with methylation of SFRP1 gene and may
Figure 5. Percentage methylation frequency and neoadjuvant therapy. The % methylation in tumors with neoadjuvant therapy (n=922
luminal; 4 basal-like and 3 triple-negative cases) and without (n=53; Mann-Whitney). There were 3 cases for which neoadjuvant therapy data was not
available.
doi:10.1371/journal.pone.0037928.g005
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possibility that gene methylation pattern in breast tissues may
contribute to altered gene expression in older AA and EA
individuals.
Recent microarray profiling of invasive breast carcinomas has
revealed 5 distinct tumor subtypes with distinct gene expression
signatures and clinical outcomes. Because AA and EA women with
breast cancer experience differences in tumor subtype presenta-
tions, we investigated methylation changes as potential biomarkers
for tumor subtypes. In the 65 cases that we tested, 14 cases were
triple-negative tumors and tended to have increased CDH13
methylation and a decreased methylation of the RASSF1A and
SFRP1 genes. The basal-like tumors (13 cases) tended to have a
decrease RASSF1A methylation whereas the luminal A tumors (21
cases) tended to have a decrease CDH13 methylation. Our data
suggests that DNA methylation reflected by the CDH13, RASSF1A
and SFRP1 locus panel might have a role in the phenotype of
breast tumor subtypes. We did not see any correlation of
methylation with lymph node, tumor grade which may mainly
reflect a limitation on the sample size used in this study.
Methylation of specific candidate genes or groups of genes has
been associated with poorer prognosis and these genes may affect
tumor aggressiveness independent of their methylation phenotype
[39–41]. Such candidate genes are being explored as potential
biomarkers for detecting breast cancer invasion and for predicting
response to neoadjuvant therapy as well as other therapeutic
intermediates. We observed that neoadjuvant therapy may affect
RASSF1A methylation suggesting that RASSF1A methylation could
actually be a useful predictive marker for neoadjuvant therapy
response. Finally, high methylation of RASSF1A, RARb2 and
CDH13 loci were associated with worse overall disease survival in
our analysis. These 3 loci tended to be more methylated in AA
compared with EA tumors supporting our hypothesis that
differences in methylation patterns may contribute to the more
aggressive and poorer disease outcome in AA women.
Consistent differences in the methylation pattern between AA
and EA breast cancer cases can be attributed to environmental
factors including dietary factors (e.g., availability of methyl
donors), or functional SNP allele frequencies. Diet-low levels of
S-adenosyl methionine (SAM), and the production of SAM
depends on dietary factors such as folate, vitamin B6, and vitamin
B12. The main role of folate is to provide one-carbon units in
several reactions necessary for DNA methylation and synthesis,
while vitamins B12 and B6 serve as cofactors in some of these
reactions [42]. Sustained low levels of these nutrients may lead to
disturbance in DNA methylation, synthesis, and repair, possibility
influencing breast cancer disparity.
In conclusion, ongoing studies clearly demonstrates differential
DNA methylation patterns in AA and EA breast cancer cases that
may represent an integration of lifestyle and genetic predisposing
factors resulting in altered patterns of gene expression and
differences in clinical outcome and behavior.
Supporting Information
Figure S1 Quantitative DNA methylation analysis in
human breast tissues not exposed to neoadjuvant
therapy. The percentage of DNA methylation levels at promoter
CpG islands were analyzed in bisulfite-modified genomic DNA
extracted from matched pairs of non-cancerous (normal) and
breast tumors (tumor) tissue samples obtained from AA and AE
cancer patients. Y axis, percentage of methylated cytosines in the
samples as obtained from pyrosequencing. X axis, normal and
Figure 6. Methylation signatures and survival. A. The sum of z-
scores for RASSF1A, RARb2 and CDH13 were significantly higher in AA
patients (p=0.035; Mann-Whitney; n=65). B. Patients with high values
for the sum of Z scores demonstrated poor outcome (p=0.085; log rank
test; n=65, adjusted for age at diagnosis, and ER status). Hazard ratio
was 2.20 with the 95% confidence interval of 0.90 to 5.42, adjusted for
age at diagnosis and ER status. The median of the sum of z-scores for all
cases was used as the cutoff.
doi:10.1371/journal.pone.0037928.g006
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each gene (Mann-Whitney). Adj. P: adjusted P value (Bonferroni).
(TIF)
Figure S2 Correlating gene methylation status and
patient characteristics. A. Gene methylation status in patients
not exposed to neoadjuvant therapy. Relative methylation
frequency (% methylation in tumor minus % methylation in
adjacent normal) stratified by race; AA (n=32) and EA (n=33;
Mann-Whitney). Adj. P: adjusted P value (Bonferroni). B.
Correlation of gene methylation and individual ancestry score.
Relative CDH13 methylation frequency stratified by ER- negative
(2) patients with age ,50 (17 cases in total; 8 AA cases and 9 EA
cases) was correlated with individual informative markers for West
African and European ancestry. P value is shown (Mann-
Whitney).
(TIF)
Pyrogram Data S1 Representative pyrogram traces for
CDH13 CpG island. Grey columns represent regions of C to T
polymorphic sites. Representative matched normal and prostate
tumor samples for African-American (AA) and European-Amer-
ican (EA) breast cancer patients are shown. Top, percentage
methylation at each CpG sites. Y-axis signal peaks proportional to
the number of nucleotides incorporated. X-axis, the nucleotide
incorporated in the pyrosequencing reaction.
(TIF)
Table S1 Primer sequences used in the pyrosequencing
analysis. U represents universal primer sequence- GGGA-
CACCGCTGATCGTTTA.
(DOC)
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